에이프로젠바이오로직스

003060KOSPI의약품 제조업

37.0 / 100

Reference Date: 2026-04-13

Financial Score11.5 / 40

News Sentiment12.5 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Declined 7.7% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Aprogen BioLogics operates two business segments: a pharmaceutical division producing synthetic drugs and a biopharmaceutical division manufacturing biologics. Its Cheongju-based Osong facility boasts world-class antibody production capacity, capable of producing over 2.8 million liters of culture media annually. The affiliated company Aprogen Pharma focuses on drug distribution, though the group reported an operating loss as of 2023.

Number of Employees

445people

Average Salary

47.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 14.804.0Point

PBR

0.18Industry Average 1.047.0Point

Half of industry avg (excellent)

ROE

-51.29Industry Average 4.420.0Point

Well below industry avg

Debt Ratio

28.93Industry Average 11.980.0Point

2.4x industry avg (risky)

Trend 2023~20250.5 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼7.1% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼3.1% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -35.2% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 251Won52-week high 73752-week low 235

1-month return1.0Point

1m -7.72% (falling)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

7 totalPositive 0Neutral 7Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-04-03
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
Neutral정기주주총회결과2026-03-30
Neutral[기재정정]주식등의대량보유상황보고서(일반)2026-03-30
Neutral주식등의대량보유상황보고서(일반)2026-03-27